# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Rachel Carson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML041-SYN-TD
- Date: 1960-04-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Vance-Okonkwo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review two weeks after left lumpectomy, with the pathology. **S**

## History of present illness

Ms. Carson returns two weeks after a left lumpectomy with sentinel lymph node biopsy. The germline panel before surgery showed no pathogenic variant. She asked to hear the pathology in full and had it from Dr. Solís-Abernathy last week, and again today: the cancer was 2.3 cm, grade 2, with clear margins, and two of the three sentinel lymph nodes contained cancer, without spread beyond the node capsules (pT2 pN1a, anatomic stage IIB). She was told plainly that the cancer had reached lymph nodes under the arm, that this raises the chance of it returning, and that treatment is still given with the aim of cure. The recurrence score is 17. Last week the multidisciplinary breast team (surgery, medical oncology, and radiation oncology) reviewed the results and gave her their recommendations with the expected benefits and side effects in numbers; she took a week to read about them and has decided. The urea breath test three days ago, two weeks after she stopped omeprazole, was negative. The wound has healed and she has little pain on acetaminophen. She is writing again in the mornings. **S**

| Element | Detail |
|---|---|
| Interval change | Left lumpectomy and sentinel node biopsy two weeks ago |
| Pathology | pT2 pN1a(sn), 2 of 3 sentinel nodes, grade 2, margins clear; recurrence score 17 |
| Genetics | No pathogenic germline variant |
| Her decisions | Radiation; letrozole with ribociclib; zoledronic acid; no chemotherapy |
| Ulcer | Urea breath test negative; Helicobacter pylori eradicated |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy returning |
| Integumentary | Negative | Wounds healed; no redness or fluid |
| Musculoskeletal | Positive | Mild tightness raising the left arm; knee stiffness unchanged; no bone pain |
| Neurological | Positive | Small patch of numbness on the inner left upper arm |
| Gastrointestinal | Negative | No indigestion or black stools off omeprazole |
| Psychiatric | Positive | Some worry about the lymph nodes, sleeping better; PHQ-9 4, GAD-7 5 |

6 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for knee pain, no more than 3000 mg a day **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/76 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 58.6 kg; BMI 22.1 kg/m². All vital signs are synthetic.

PHQ-9: 4; GAD-7: 5. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Well and composed |
| Breasts | Left lumpectomy scar at 2 o'clock and axillary incision healed; mild firmness under the scar; no fluid or erythema. Right breast normal |
| Lymph nodes | No palpable axillary or supraclavicular nodes |
| Extremities | Arm circumference 25.5 cm on each side 10 cm above the elbow, the same as before surgery; left shoulder flexion 160 degrees |
| Abdomen | Soft; no epigastric tenderness |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Metastatic carcinoma in two of three left sentinel lymph nodes; pT2 pN1a(sn) M0, anatomic stage IIB** (C77.3). One or two positive sentinel nodes after breast-conserving surgery that will be followed by whole-breast radiation: axillary dissection would add arm swelling without improving survival, so it is not needed. With nodal disease, radiation to the regional lymph nodes is added. Staging scans are not needed without symptoms. **S**
   - Hypofractionated whole-breast and regional nodal radiation with a tumor-bed boost, starting in two weeks, booked in the afternoons at her request.
2. **Left breast cancer, hormone receptor positive, HER2 negative, after lumpectomy** (C50.412). Postmenopausal with one to three positive nodes and a recurrence score of 17: chemotherapy would add no meaningful benefit. Stage II node-positive disease makes her eligible for adjuvant ribociclib with an aromatase inhibitor, which in its trial lowered the risk of invasive recurrence by about 3 percentage points at three years, at the cost of fortnightly blood tests at first, ECG checks, a low white count, and rarely liver injury. She chose to take it. **S**
   - After radiation: letrozole 2.5 mg daily for at least five years with ribociclib 400 mg on days 1 to 21 of each 28-day cycle for three years.
   - Before ribociclib: ECG, blood count, liver tests, and electrolytes; a list of drugs that prolong the QT interval, to avoid.
   - Adjuvant zoledronic acid every six months for three years, after a dental check, with a baseline DXA.
   - Mammogram six to twelve months after radiation, then yearly.
3. **Duodenal ulcer with Helicobacter pylori** (K26.9). Urea breath test negative: infection eradicated and the ulcer treated. Resolved. **S**
   - No further acid suppression; continue to avoid nonsteroidal anti-inflammatory drugs.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Post-operative wound, shoulder, and arm check | After surgery | Completed today | Wounds healed; shoulder flexion 160 degrees; no seroma |
| Laboratory | Surgical pathology and recurrence score | After surgery | Up to date | pT2 pN1a(sn), margins clear; recurrence score 17 |
| Laboratory | Germline genetic testing | At diagnosis | Up to date | No pathogenic variant; result given before surgery |
| Self-management | Disclosure of the pathology and shared decision-making | At every result | Completed today | Pathology given in full in plain words with a copy; benefits and harms of each treatment given in numbers; decisions made by her after a week to consider them |
| Examination | Lymphedema assessment and risk-reduction counseling | Every visit | Completed today | 25.5 cm on each side, unchanged from the pre-operative baseline; counseled on early signs |
| Referral | Medical and radiation oncology | After surgery | Up to date | Seen last week at the multidisciplinary breast clinic |
| Imaging | CT, bone scan, or PET for distant spread | Only with symptoms or clinical stage III | Not indicated | Pathologic stage IIB without symptoms of spread |
| Laboratory | Tumor markers | Not recommended for early breast cancer | Not indicated | Not ordered |
| Medication safety | Ribociclib baseline ECG, blood count, liver tests, and electrolytes | Before the first dose | Due | At the visit when letrozole and ribociclib start, after radiation |
| Imaging | Bone density (DXA) | Baseline at aromatase inhibitor start | Ordered | Booked for the day letrozole starts |
| Medication safety | Dental assessment before zoledronic acid | Before the first infusion | Ordered | Dental check booked before the first infusion |
| Survey | Distress, depression, and anxiety screen (PHQ-9 and GAD-7) | At periodic intervals | Completed today | PHQ-9 4 and GAD-7 5 |
| Laboratory | Helicobacter pylori test of cure | At least four weeks after antibiotics and two weeks off a proton pump inhibitor | Up to date | Urea breath test three days ago: negative |

## Goal progress

- Receive the biopsy result in person within ten days, explained in plain words, with a copy of the report. Outcome by 1960-03-18: Told the diagnosis in person nine days after presentation, with the pathology report in hand; teach-back confirmed her understanding. **S**
- Make each treatment decision herself after hearing the options, benefits, and harms. Outcome by 1960-04-20: Chose breast-conserving surgery and, after the pathology, radiation, letrozole, ribociclib, and zoledronic acid. **S**
- Complete surgery and radiation, then start endocrine therapy, within four months of diagnosis. In progress; target 1960-06-15. **S**
- Take adjuvant systemic therapy safely, with every safety check the drugs require done on schedule. In progress; target 1960-12-07. **S**
- Keep writing at least four mornings a week through treatment. In progress; target 1960-12-07. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025), National Comprehensive Cancer Network
- Code of Medical Ethics Opinion 2.1.3: Withholding Information from Patients (2016), American Medical Association
- Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol 2021;39(27):3056-3082 (2021), American Society of Clinical Oncology and Ontario Health (Cancer Care Ontario)
- Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2024;42(18):2233-2235 (2024), American Society of Clinical Oncology
- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol 2022;40(7):787-800 (2022), American Society of Clinical Oncology and Ontario Health (Cancer Care Ontario)
- ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2024;119(9):1730-1753 (2024), American College of Gastroenterology

## Follow-up

- Radiation starting in two weeks. Primary care visit after radiation, on the day letrozole and ribociclib start. **S**
- Next scheduled visit 1960-06-15: start of letrozole, ribociclib, and zoledronic acid after radiation. **S**
